Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 11/08/17 at 09:58am

Another week, another busy week in pharma. The last seven days have seen some remarkable strides in the diabetes space, with news of a new immunotherapy treatment which could halt the progression of the type 1 form of the disease. We also saw the biggest investment made in a biotech ever, while many readers also took note of the perturbing discovey that chemotherapy can spread cancer as well as treat it.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Pioneering immunotherapy halts progression of type 1 diabetes

In a first for the disease area, an immunotherapy treatment for diabetes has proven its ability to halt the progression of the type 1 form of the illness.

9. Diabetes drug holds promise to slow Parkinson’s progression

A breakthrough piece of research that has found a repurposed use for a diabetes drug that could slow down the progression of the disease has been welcomed by scientists and charity groups.

8. Bristol-Myers Squibb’s $2.3 billion gamble to boost cancer pipeline

Bristol-Myers Squibb has agreed a deal to acquire IFM Therapeutics for a potential $2.3 billion.

7. FDA awards orphan status to new brain cancer vaccine

The FDA has announced that it has awarded orphan drug status to the vaccine SurVaxM for patients with glioblastoma, the most common form of brain cancer.

6. Japanese telecom giant injects $1.1bn into Swiss biotech in largest-ever investment of its kind

In possibly the biggest single biotech investment ever made, Swiss biotech firm Roivant has received a $1.1 billion cash injection thanks to an investment from Japanese telecom giant SoftBank.

5. Study finds that women have more active brains than men

In research that will have many women nodding their brain-boxes, a study has found that analysis of thousands of brain scans showed that women had higher overall levels of activity.

4. Merck scores expanded NICE recommendation in head, neck and oral cancer

NICE has decided to expand its recommendation of Erbitux (cetuximab) to include its use as a first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity.

3. Bayer secures one-two treatment for liver cancer after EU approval

Bayer has announced that it has received European Commission approval for its treatment of hepatocellular carcinoma, a type of liver cancer, as second-line treatment. This means that Stivarga will be available to use after Bayer’s other therapy, Nexavar, used in first-line treatment.

2. Chemotherapy can spread breast cancer to lungs, study finds

Researchers at Ohio State University have discovered that, as well as forming a key part of treatment strategies to fight breast cancer, chemotherapy can facilitate the spread of the disease to the lungs.

1. Shire shifts vaccine facility from Baxalta deal to MSD

Shire has sold off its 340,000-square-foot facility that was leftover from the Baxalta deal to MSD Animal Health.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches